{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Lutetium_Lu_177__Vipivotide_Tetraxetan",
  "nciThesaurus": {
    "casRegistry": "1703749-62-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.",
    "fdaUniiCode": "G6UF363ECX",
    "identifier": "C148145",
    "preferredName": "Lutetium Lu 177  Vipivotide Tetraxetan",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "177Lu-PSMA-617",
      "177Lu-labeled PSMA-617",
      "LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN",
      "Lu177-PSMA-617",
      "Lutetium Lu 177  Vipivotide Tetraxetan",
      "Lutetium Lu 177-PSMA-617"
    ]
  }
}